Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

NCT02477800 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02477800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02477800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Terminated
Start date
August 13, 2015
Completion date
August 8, 2019
Enrollment
1,653 (actual)
Sites
181

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease